VORTEX
BIOTECHNOLOGY CORPORATION
Novel Anti-Cancer Biotechnology
ABOUT US
Novel science. Proven process.
Vortex Biotechnology is committed to the discovery of novel anticancer targets and the development of unique medicines that block activity at the target sites. Headed by a CEO who has developed drugs both in the clinic and the laboratory, Vortex is using proven structure-based drug design to create robust drug candidates which can be applied across multiple tumor types.
Vortex Biotechnology is currently developing VBT-34, an oral stimulator of RNA degradation, for the treatment of both hematological and solid tumors, as well as exploring other unique oncology targets and pathways. Our successful approach is tumor-agnostic with unique targets that are the key to discovering new treatments for cancer patients with unmet medical needs.
OUR FOCUS
Novel science. Proven process.
DNA allows for RNA formation. RNA leads to proteins that drive cancer. Biotechnology must therefore target RNA activity to block
cancer growth.
Vortex Biotechnology Corp. pursues novel targets that regulate the activity of specific classes of RNAs, either stimulating their degradation or enhancing their half-life. This effort involves searching for novel cancer biology, developing cutting edge medicinal chemistry, and creating a robust pipeline of new drug candidates.
Our leadership has experience both in the laboratory and the development of clinical trials as well as the experience of managing the complexities of patient care during novel drug treatments. Vortex's team also has a strong history of close interactions with the National Cancer Institute and Biopharma, as well as well as with multiple National Cancer Institute Cancer Centers.
We focus on:
-
Compelling biological validation
-
First-in-class drug candidates
-
Determining target structures
-
Paths to Clinical proof of concept
-
Partnerships with NCI and Biopharma
LEADERSHIP
Andrew S. Kraft, M.D.
Founder and Chief Executive Officer
Dr. Kraft is a leading scientist and physician in cancer and translational therapy. He was previously the director of two National Cancer Institute Cancer (NCI) Centers. In his laboratory and the clinic, he has developed novel anticancer compounds. He has also developed scientists, led teams focused drug discovery, and managed phase 1-3 trials in the clinic. He is both the founder of Vortex Biotechnology and the laboratory developer of the company’s lead compound.
